Deferasirox lacks in vitro activity against fusarium and scedosporium species and black molds

Virulence

Volumn 2, Issue 3, 2011, Pages 257-258

  Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alternaria; Bipolaris; Deferasirox; Fusarium; Scedosporium

Indexed keywords

DEFERASIROX; ANTIFUNGAL AGENT; BENZOIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ARTICLE; FUNGAL STRAIN; FUNGUS ISOLATION; FUSARIUM; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOULD; NONHUMAN; SCEDOSPORIUM; SCEDOSPORIUM APIOSPERMUM; SCEDOSPORIUM PROLIFICANS; DRUG EFFECT; FUNGUS; HUMAN; LETTER; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION;

ALTERNARIA; BIPOLARIS; FUSARIUM; SCEDOSPORIUM;

ANTIFUNGAL AGENTS; BENZOIC ACIDS; FUNGI; FUSARIUM; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; SCEDOSPORIUM; TRIAZOLES;

EID: 85046979900     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.2.3.15660     Document Type: Article

References (9)

1. Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117:2649-2657.
2. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91:986-989.
3. Clinical Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, vol. Clinical and Laboratory Standards Institute, Wayne PA 2008; 2.
4. Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS Collaborative Study. J Clin Microbiol 2002; 40:3204-3208.
5. Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, et al. Randomized phase II trial of deferasirox (Exjade), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91:873-880.
6. Bertrand S, Larcher G, Landreau A, Richomme P, Duval O, Bouchara JP. Hydroxamate siderophores of Scedosporium apiospermum. Biometals 2009; 22:1019-1029.
7. Greenshields DL, Liu G, Feng J, Selvaraj G, Wei Y The siderophore biosynthetic gene SID1, but not the ferroxidase gene FET3, is required for full Fusarium gra-minearum virulence. Mol Plant Pathol 2007; 8:411-421.
8. Ibrahim AS, Gebremariam T, French SW, Edwards JE Jr, Spellberg B. The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. J Antimicrob Chemother 2010; 65:289-292.
9. Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J Clin Invest 1993; 91:1979-1986.